OSI PHARMACEUTICALS, LLC Patent applications |
Patent application number | Title | Published |
20140088114 | FUSED BICYCLIC KINASE INHIBITORS - Compounds of Formula (I), pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of MET, RON, ALK, IR, or IGF-1R. This Abstract is not limiting of the invention. | 03-27-2014 |
20130261306 | PREPARATION OF C-PYRAZINE-METHYLAMINES - A process for preparing a compound of formula (I) or a salt thereof: (I) wherein R1 is H or optionally substituted aryl or heteroaryl; comprising reacting 2,3-dichloropyrazine with a suitable diaryl imine followed by hydrolysis. | 10-03-2013 |
20130261086 | MACROCYCLIC KINASE INHIBITORS - Compounds of Formula (I): wherein variables are defined herein, and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers for which FAK inhibition is beneficial. | 10-03-2013 |
20130253197 | FUSED BICYCLIC KINASE INHIBITORS - Compounds of Formula I, as shown below and defined herein: | 09-26-2013 |
20130231306 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS - Compounds of Formula 1, as shown below and defined herein: | 09-05-2013 |
20130210026 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO KINASE INHIBITORS - The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with inhibitors of EGFR kinase, PDGFR kinase, or FGFR kinase. Based on the surprising discovery that tumors cells after having undergone an EMT, while being mesenchymal-like, still express characteristics of both epithelial and mesenchymal cells, and that such cells have altered sensitivity to inhibition by receptor protein-tyrosine kinase inhibitors, in that they have become relatively insensitive to EGFR kinase inhibitors, but have frequently acquired sensitivity to inhibitors of other receptor protein-tyrosine kinases such as PDGFR or FGFR, methods have been devised for determining levels of specific epithelial and mesenchymal biomarkers that identify such “hybrid” tumor cells (e.g. determination of co-expression of vimentin and epithelial keratins), and thus predict the tumor's likely sensitivity to inhibitors of EGFR kinase, PDGFR kinase, or FGFR kinase. Improved methods for treating cancer patients with EGFR, PDGFR or FGFR kinase inhibitors that incorporate such methodology are also provided. | 08-15-2013 |
20130190496 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 07-25-2013 |
20130165651 | FUSED BICYCLIC mTOR INHIBITORS - Compounds represented by Formula (I) | 06-27-2013 |
20130137975 | PET IMAGING - A method for determining whether to administer a therapeutically effective amount of a receptor tyrosine kinase-inhibiting drug for tumor treatment, by determining a glucose uptake response in the tumor of a mammal. | 05-30-2013 |
20130072495 | FUSED BICYCLIC KINASE INHIBITORS - Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as but not limited to tumors driven at least in part by at least one of RON, MET, IR, IGF-1R, or ALK. This Abstract is not limiting of the invention. | 03-21-2013 |
20130005733 | COMBINATION ANTI-CANCER THERAPY - Methods and compositions for treating cancer comprising administering to a patient inhibitors of mT0RC1/C2, IGF-1 R, and IR. In some aspects, a combination of an mT0RC1/C2 inhibitor and an IGF-1 R/IR inhibitor is employed. Other aspects are described herein. | 01-03-2013 |
20120329826 | SUBSTITUTED-5-AMINOPYRROLO/PYRAZOLOPYRIDINES - Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by RON and/or MET. | 12-27-2012 |
20120302572 | USE OF EMT GENE SIGNATURES IN CANCER DRUG DISCOVERY, DIAGNOSTICS, AND TREATMENT - The present invention provides diagnostic methods for assessing the EMT status of tumor cells, and for predicting the effectiveness of treatment of a cancer patient with an EGFR or IGF-1R kinase inhibitor, utilizing an EMT gene signature index score. The present invention further provides methods for treating patients with cancer that incorporate these methods. | 11-29-2012 |
20120128670 | mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY - Cancer therapy comprising treatment with an mTOR inhibitor, such as a dual mTORC1/mTORC2 inhibitor, such as OSI-027, in combination with an angiogenesis inhibitor. | 05-24-2012 |